HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
November 10 2022 - 9:00AM
Heart Test Laboratories, Inc. d/b/a
HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the
“Company”), a medical technology company focused on saving
lives by making an ECG (also known as an EKG) a far more valuable
screening tool through the use of AI, today announced that an
independent study utilizing its MyoVista® proprietary technology
was featured in Advocate Aurora Health’s Journal of
Patient-Centered Research and Reviews, an open access,
peer-reviewed medical journal devoted to advancing patient centered
care practices, health outcomes, and patient experiences.
The publication concluded that the MyoVista®
technology ECG-derived machine learning model “provides a
cost-effective strategy for predicting patient subgroups in whom an
integrated milieu of systolic and diastolic dysfunction is
associated with a high-risk of major adverse cardiovascular events
(MACE).”
Key study highlights:
- Patients (n=518) from West Virginia University served as
the validation set and were followed up over a three-year period
(38-months) for clinical outcomes including MACE rehospitalization
and cardiac death.
- Results demonstrate the potential of AI-ECG algorithms
for rapid decision-making in an office-based setting to evaluate
and monitor the progress of the patient and justify appropriate
downstream referral for additional tests like echocardiography or
other interventions.
- The Deep Neural Network (DNN) AI-ECG model demonstrated
significantly increased probability for identifying patients at
high-risk compared to low risk of MACE (21% vs 3%; P<0.001)
- The AI-ECG model results were similar to an echo-based
model (21% vs 5%; P<0.001), suggesting comparable utility.
- Data used to develop the AI-ECG algorithm was collected
from a multi-center trial, which included 727 patients from the
Icahn School of Medicine at Mount Sinai, The University of
California Los Angeles and Windsor Cardiac Center, Windsor
Ontario.
“This independent study demonstrates the
opportunity that AI-ECG algorithms could bring to improving health
outcomes. I believe the solution to unnecessary cardiac deaths will
come from low-cost, front-line screening using AI-ECGs. Imagine the
day where you can go to your primary care physician and a simple
20-second ECG test shows not only whether you have early-stage
heart disease, but also whether you are at high-risk of a major
adverse cardiovascular event in the next three years,” stated
Andrew Simpson, CEO of HeartSciences. “There are millions of ECGs
conducted every week and HeartSciences is at the leading edge of
commercialization in the field of adding new clinical indications
to the ECG.”
The study trained the AI-ECG model against an
echo-derived model for predicting MACE events combining multiple
parameters for identifying patient phenogroups at risk for MACE.
Nine echo parameters were included for determining patient risk:
ejection fraction; left ventricular mass index; left atrial volume
index; early diastolic transmitral flow velocity (E); late
diastolic transmitral flow velocity (A); E/A ratio; early diastolic
relaxation velocity (e’); E/e’ ratio; and tricuspid regurgitation
peak velocity.
The final AI-ECG model included 51 ECG features,
of which the majority were MyoVista® CWT frequency features (n=26,
51%), followed by traditional ECG features derived from the
MyoVista® (n=23, 45%) and clinical features were age and past
medical history of coronary artery disease (n=2, 4%).
“The extracted frequency parameters provided via
MyoVista®’s CWT technology represented the majority of the
statistically significant data variables used to develop the
algorithm using AI-based variable reduction techniques,” stated
Mark Hilz, COO of HeartSciences. “We believe this clearly
demonstrates the value of our signal processing technology and its
ability to identify additional meaningful information from the
electrical signal of the heart.”
The deep neural network (DNN) model showed
robust classification of patients with areas under the receiver
operating characteristic curves (AUC) of 0.84 (95% CI: 0.80–0.87).
The ECG-predicted model demonstrated an increased probability for
MACE in high-risk compared to low-risk patients (21% vs 3%;
P<0.001). The results were similar to the
echo-trained model (21% vs 5%; P<0.001), suggesting a comparable
utility of the MyoVista® technology compared to echo to identify
patients at risk of MACE events.
As reported in the publication, cardiovascular
disease is the leading cause of morbidity and mortality globally,
resulting in estimated health care costs of more than $200 billion
in the United States annually. Effective, economical, and
personalized prevention and risk-stratification strategies are
imperative to mitigate this burden.
To read the full publication, please
visit: https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1893&context=jpcrr
1Source: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
About HeartSciencesHeart Test Laboratories,
Inc. d/b/a HeartSciences is a medical technology company focused on
applying innovative AI-based technology to an ECG (also known as an
EKG) to expand and improve an ECG’s clinical usefulness. Millions
of ECGs are performed every week and the Company’s objective is to
improve healthcare by making an ECG a far more valuable cardiac
screening tool, particularly in frontline or point-of-care clinical
settings. HeartSciences’ first product candidate for FDA clearance,
the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG
that is also designed to provide diagnostic information related to
cardiac dysfunction which has traditionally only been available
through the use of cardiac imaging. The MyoVista® also provides
conventional ECG information in the same test. The business model,
which involves the use of the MyoVista® device and consumables for
each test, is expected to be “razor-razorblade” as the electrodes
used with the MyoVista® are proprietary to HeartSciences, and new
electrodes are required for every test performed.For more
information, please visit: https://www.heartsciences.com.
Twitter: @HeartSciencesSafe Harbor StatementThis
announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements
are made under the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995 and are relating to the
Company's future financial and operating performance. All
statements, other than statements of historical facts, included
herein are "forward-looking statements" including, among other
things, statements about HeartSciences’ beliefs and expectations.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control. The
expectations reflected in these forward-looking statements involve
significant assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Potential risks and
uncertainties include, but are not limited to, risks discussed in
HeartSciences’ filings with the U.S. Securities and Exchange
Commission at www.sec.gov. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.For investor and media inquiries,
please contact:Investor Relations:Crescendo
Communications, LLCPhone: (212)
671-1021Email: HSCS@crescendo-ir.com
Company:Gene GephartPhone: +1-737-414-9213
(US)Email: investorrelations@heartsciences.com
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Sep 2023 to Sep 2024